Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 644 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR FDA Approves Ivosidenib for Myelodysplastic Syndromes November 9, 2023 Seeing a Promising Future for Progress against Childhood Cancer September 16, 2021 BRAF/MEK Inhibition May Be a Viable Treatment Strategy Across the Majority... August 11, 2020 Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer March 11, 2019 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide Washington Farmers Harvest Crops For Neighbor With Stage Four Cancer Singer Rebecca Crews, Wife Of Terry Crews, Diagnosed With Breast Cancer... Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response
